Washington Correspondent @statnews. Subscribe to our newsletter D.C. Diagnosis at https://t.co/t19n377jX6 ✉️: [email protected]
United States (National)
Not enough data
Rachel Cohrs focuses on national coverage of healthcare, pharmaceuticals, and government policy in the United States. She frequently reports on legal and regulatory developments within these sectors.
To effectively reach out to Rachel, consider providing insights from experts with deep knowledge of U.S. healthcare policies, pharmaceutical industry regulations, and legal aspects affecting Medicaid and Medicare programs. Additionally, pitches offering commentary or analysis related to significant government announcements or policy changes impacting the healthcare sector are likely to capture her attention.
As Rachel's focus is primarily national (United States), it would be beneficial for sources to provide localized perspectives relevant to U.S. federal policies or specific regional implications within the country.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By Rachel Cohrs and John Wilkerson Feb. 26, 2024 W ASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate
Congress has decided not to pass a site-neutral hospital pay policy along with an upcoming government funding package.
By Rachel Cohrs Feb. 29, 2024 You're reading the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
By: Rachel Cohrs
A federal judge on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program.
By: John Wilkerson, Rachel Cohrs
By John Wilkerson and Rachel Cohrs March 3, 2024 W ASHINGTON — Doctors will get a 1.68% pay hike in Medicare starting March 9 under a deal struck over the weekend to fund part of the government.
By: Rachel Cohrs
The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.
By: Rachel Cohrs
President Biden wants to more than double the size of Medicare’s new drug price negotiation program, he'll say in his State of the Union address Thursday.
Pharma industry giants deployed a half-dozen lawyers in a bid to dismantle Medicare’s new drug price negotiation program.
By: Rachel Cohrs
By Rachel Cohrs March 14, 2024 W ASHINGTON — Novo Nordisk's newly won permission to market the heart benefits of its obesity drug Wegovy
Our latest edition of D.C. Diagnosis includes the backstory of BIO's relationship with WuXi, a major endorsement of site-neutral payments, and the financial fallout of a WuXi ban.
(833) 317-6278 
